OX40 (TNFRSF4) Tracks Immune Infiltration in Small Cell Lung Cancer and Shows a Cohort-Specific, Non-Replicated Association with the POU2F3/SCLC-P Subtype: A Multi-Source In Silico Analysis
Mehmet Turan Özer, Faruk Recep Özalp · 2026
Read OX40 (TNFRSF4) Tracks Immune Infiltration in Small Cell Lung Cancer and Shows a Cohort-Specific, Non-Replicated Association with the POU2F3/SCLC-P Subtype: A Multi-Source In Silico Analysis by Mehmet Turan Özer, Faruk Recep Özalp (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13566540.txt.
Description
Mehmet Turan Özer and Faruk Recep Özalp wrote a 2026 analysis of OX40, an immune co-stimulator, in small cell lung cancer. OX40 agonist drugs are in development, but the receptor's role in this aggressive cancer was uncharacterized. The authors mined several public datasets rather than running new experiments.
They combined a discovery cohort, a public tumor dataset, drug-screened cell lines, and a single-cell atlas of over 77,000 cells. High OX40 expression showed only a weak, non-significant survival trend. No drug, among 658 tests, linked significantly to its level. OX40 tracked immune infiltration strongly and sat mostly on T cells, not tumor cells. It was enriched in one molecular subtype in the discovery data. That subtype link, however, failed to replicate independently. The authors present the finding as cohort-specific, a caution against overreading single datasets.
Catalog record
| CREATOR | Mehmet Turan Özer, Faruk Recep Özalp |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |